Cited by 362Heart Failure Treatment and ManagementCardiac pacing and defibrillation studiesCardiovascular Function and Risk Factors

2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction

Open access
Maddox, Thomas M., Januzzi, James L., Allen, Larry A., Breathett, Khadijah, Brouse, Sara, Butler, Javed, Davis, Leslie L., Fonarow, Gregg C. +9 more·2024·Journal of the American College of Cardiology

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2023.12.024

Cites

250 of 250 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • People with diabetes may present with a wide spectrum of heart failure, including HFpEF, HFmrEF, or HFrEF.

    “People with diabetes may present with a wide spectrum of heart failure, including heart failure with preserved ejection fraction (HFpEF), heart failure with mildly reduced ejection fraction (HFmrEF), or heart failure with reduced ejection fraction (HFrEF) (12,13).”

    From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [12]

    Section 4.9 (page unavailable) says diabetes is common among people with HF and is strongly associated with incident HF. The paper focuses on HFrEF; our copy does not establish that people with diabetes may present across all three listed ejection-fraction categories, particularly HFpEF and HFmrEF. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

5 of the 255 references couldn’t be matched to a known paper.

Research works printed but not linked: 11

  1. [37]37. Mann D.L., Greene S.J., Givertz M.M., et al. Sacubitril/valsartan in advanced heart failure with reduced ejection fraction: rationale and design of the LIFE Trial. J Am Coll Cardiol HF. 2020;8:789-799. Go to Citation Google Scholar
  2. [72]72. Boehringer Ingelheim Pharmaceuticals. (2020, July 30). Empagliflozin meets primary endpoint in Phase III heart failure trial [Press Release]. Accessed July 2023. https://www.boehringer-ingelheim.com/press-release/emperor-reduced-heart-failure-toplineresults. Google Scholar a [...] should be added, barring contraindications. b [...] be considered for symptom improvement.
  3. [73]73. Solomon S.D., Jhund P.S., Claggett B.L., et al. Effect of dapagliflozin in patients with hfref treated with sacubitril/valsartan: the DAPA-HF Trial. J Am Coll Cardiol HF. 2020;8:10: 811-818. Go to Citation Google Scholar
  4. [83]83. DeFilippis E.M., Reza N., Donald E., et al. Considerations for heart failure during the COVID-19 pandemic. J Am Coll Cardiol HF. 2020;8:681-691. Go to Citation Google Scholar
  5. [92]92. Daubert M.A., Adams K., Yow E., et al. NT-proBNP goal achievement is associated with significant reverse remodelings and improved clinical outcomes in HFrEF. J Am Coll Cardiol HF. 2019;7:158-168. Go to Citation Google Scholar
  6. [94]94. Myhre P.L., Prescott M.F., Murphy S.P., et al. Early B-Type natriuretic peptide change in HFrEF patients treated with sacubitril/valsartan: a pooled analysis of EVALUATE-HF and PROVE-HF. J Am Coll Cardiol HF. 2022;10:119-128. Go to Citation Google Scholar
  7. [125]125. McAlister F.A., Stewart S., Ferrua S., McMurray J.J. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol. 2004;44:810-819. Go to Citation Crossref PubMed Google Scholar
  8. [148]148. Vaduganathan M., Fonarow G.C., Greene S.J., et al. Contemporary treatment patterns and clinical outcomes of comorbid diabetes mellitus and HFrEF: The CHAMP-HF Registry. J Am Coll Cardiol HF. 2020;8:469-480. Go to Citation Google Scholar
  9. [191]191. Berardi C., Braunwald E., Morrow D.A., et al. Angiotensin-neprilysin inhibition in Black Americans: data from the PIONEER-HF Trial. J Am Coll Cardiol HF. 2020;8:859-866. Go to Citation Google Scholar
  10. [199]199. Pandey A., Kitzman D., Reeves G. Frailty is interwined with heart failure: mechanisms, prevalence, prognosis, assessment and management. J Am Coll Cardiol HF. 2019;7:1001-1011. Go to Citation Google Scholar
  11. [202]202. Mozaffarian D., Benjamin E.J., Go A.S., et al. Heart disease and stroke statistic - 2016 update: a report from the American Heart Association. Circulation. 2016;133:e38-e360. Go to Citation Crossref PubMed Google Scholar

Cited by

Sorted by citations

Authors
Maddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Brouse, S., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., Masoudi, F. A., Motiwala, S. R., Oliveros, E., Walsh, M. N., Wasserman, A., Yancy, C. W., & Youmans, Q. R.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2024-04
Volume
83
Issue
15
Pages
1444-1488
ISSN
0735-1097 (ISSN-L)
OpenAlex
W4392581840
Cited by
362
References
255
Citations by year
2026: 181 · 2025: 133 · 2024: 48
FWCI
100.60
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
heart failure with reduced ejection fraction, expert consensus, heart failure treatment, guideline recommendations
MeSH terms
Cardiology, Cardiovascular System, Heart Failure, Humans, Stroke Volume, United States

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review